Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI

Phase 4 Completed 50 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedSingle-groupOpen-labelTreatment

Summary

In light of tigecycline's activity against these resistant bacteria, tigecycline may represent a viable new therapy for complicated intra-abdominal infections.

Timeline

Start: 2006-08
Primary completion: —
Completion: 2007-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tigecycline	Small molecule	—	—

Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI

Summary

Timeline

Drugs

Indications